Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

INCB123667-203 Incyte/GOG-3129

Trial Overview

Official Title

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)

Study Purpose

To understand how well INCB123667 works, how safe it is, and how well it is tolerated in people with platinum-resistant ovarian cancer whose tumors have high levels of cyclin E1.

Diagnosis

Platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with high levels of cyclin E1

Eligibility

1-4 prior lines of systemic treatment, including prior bevacizumab; must have received prior mirvetuximab if FOLR1-positive; ability to take medication orally; tumor tissue available for central testing

Intervention

Participants will receive continuous treatment with INCB123667 as long as they derive benefit and do not meet any criteria for treatment discontinuation.

For more information, click the link below:

https://clinicaltrials.gov/study/NCT07023627?term=gog-3129&rank=1

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Female
Age
18 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
INCB123667-203 Incyte/GOG-3129
Related Specialties